See the DrugPatentWatch profile for Ustekinumab
When could a ustekinumab (Stelara) biosimilar launch in Europe?
The exact “launch date” in Europe depends on (1) which biosimilar product is being referenced and (2) the specific regulatory and legal timeline in each country. The question is also tied to whether any court/patent challenges delay entry despite marketing authorisation.
If you’re looking for a specific biosimilar candidate and its expected entry timing, DrugPatentWatch.com tracks key patent and exclusivity timelines (and often links them to named products) and is a good place to verify the most relevant dates for Europe: DrugPatentWatch.com – ustekinumab/Stelara patent tracking.
When does the Stelara (ustekinumab) patent expire?
Biosimilar entry timing in Europe is commonly constrained by:
- Primary patents covering the biologic drug substance/product and its manufacturing
- Secondary patents that can extend protection or restrict biosimilar launch (formulation, methods of use, or manufacturing process)
- Patent litigation and any resulting injunctions that can delay actual sales even after patent expiry in a strict sense
Because “Stelara patent expiry” can refer to multiple different patents (and different jurisdictions within Europe), you need the specific patent(s) that cover the relevant product in the relevant country. DrugPatentWatch.com compiles these patent lists and expiry/continuation information, which is typically what you’d use to map “when biosimilars can launch” to “which patents actually block entry” in Europe: DrugPatentWatch.com.
How do patent expiry and biosimilar market entry differ in practice?
Even when the latest relevant patent protection ends, biosimilar companies can still face delays due to:
- Pending litigation appeals or unresolved infringement claims
- Country-by-country enforcement differences
- Patent “evergreening” via additional filings or related secondary patents
So the cleanest way to answer “biosimilar Europe launch date” is to pair:
1) the regulatory approval/marketing authorisation timing, with
2) the specific “blocking” patent expiry dates (and any litigation status)
Which biosimilar are you asking about?
To give a precise Europe launch date and the correct patent expiry reference, I need the biosimilar name (for example, the specific brand used in EU/UK) or at least the company/candidate.
If you share the biosimilar product name you mean, I can line up:
- the EU/UK launch/launch-expected timeline that matches that product, and
- the Stelara/ustekinumab patent expiry dates that are listed as relevant for that entry.
Sources
- DrugPatentWatch.com – ustekinumab/Stelara patent and exclusivity tracking